ECT Schizophrenia Serotonin Study

This study is not yet open for participant recruitment.

Verified by Sha’ar Menashe Mental Health Center, May 2008

Sponsored by:	Sha’ar Menashe Mental Health Center
Information provided by:	Sha’ar Menashe Mental Health Center
ClinicalTrials.gov Identifier:	NCT00278668

Purpose

We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT

Condition	Phase
Schizophrenia	Phase I

MedlinePlus related topics: Schizophrenia

Drug Information available for: Escitalopram Benzetimide Citalopram Citalopram hydrobromide Dexetimide Escitalopram oxalate Serotonin

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy

Further study details as provided by Sha’ar Menashe Mental Health Center:

Estimated Enrollment:	15
Study Start Date:	October 2006
Estimated Study Completion Date:	October 2006

Detailed Description:

We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Participants must meet DSM-IV criteria for schizophrenia, as assessed by the Structured Clinical Interview - Patient Version (SCID) (First et al., 1995).

Ages 18 -55 Men and/or women -

Exclusion Criteria:

History of neurological disorders, active substance abuse in the previous 3 months.
Estimated IQ less then 70.
SSRIs treatment 4 weeks prior to the study.
Any subject suffering from inflammatory fever disease will be excluded from the study.

-

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00278668

Contacts

Contact: Avi Peled, MD

972522844050

av_peled@netvision.net.il

Sponsors and Collaborators

Sha’ar Menashe Mental Health Center

Investigators

Principal Investigator:	Avi Peled, MD	Shaar Menashe MHC
Principal Investigator:	Ilan Modai, M.D. MHA	Shaar Menashe
Principal Investigator:	Moshe Rehavi, Ph.D.	TAU

More Information

Study ID Numbers:	123.ctil
Study First Received:	January 16, 2006
Last Updated:	May 20, 2008
ClinicalTrials.gov Identifier:	NCT00278668
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:

Schizophrenia
Mental Disorders
Psychotic Disorders
Dexetimide

Citalopram
Serotonin
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on January 16, 2009